Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yulia Ron

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
United European Gastroenterology Journal|August 19, 2020
Vedolizumab is effective and safe in elderly inflammatory bowel disease patients: a binational, multicenter, retrospective cohort studyNathaniel Aviv Cohen, Nikolas Plevris, Uri Kopylov, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|September 3, 2018
Effectiveness and safety of vedolizumab for maintenance treatment in inflammatory bowel disease-The Israeli real world experienceUri Kopylov, Irit Avni-Biron, Yulia Ron, et al.
Inflammatory Bowel Diseases|February 9, 2017
Efficacy and Safety of Vedolizumab for Induction of Remission in Inflammatory Bowel Disease-the Israeli Real-World ExperienceUri Kopylov, Yulia Ron, Irit Avni-Biron, et al.
Alimentary Pharmacology & Therapeutics|September 28, 2022
Ustekinumab during pregnancy in patients with inflammatory bowel disease: a prospective multicentre cohort studyIrit Avni-Biron, Tali Mishael, Eran Zittan, et al.
The Lancet. Gastroenterology & Hepatology|November 5, 2021
The Crohn's disease exclusion diet for induction and maintenance of remission in adults with mild-to-moderate Crohn's disease (CDED-AD): an open-label, pilot, randomised trialHenit Yanai, Arie Levine, Ayal Hirsch, et al.
Journal of Crohn'S & Colitis|May 9, 2024
Faecal Transplantation for Ulcerative Colitis From Diet Conditioned Donors Followed by Dietary Intervention Results in Favourable Gut Microbial Profile Compared to Faecal Transplantation AloneHaim Leibovitzh, Chen Sarbagili Shabat, Ayal Hirsch, et al.
United European Gastroenterology Journal|March 28, 2020
Safety and effectiveness of ustekinumab for induction of remission in patients with Crohn's disease: A multicenter Israeli studyAriella Bar-Gil Shitrit, Ami Ben-Ya'acov, Matan Siterman, et al.
Journal of Crohn'S & Colitis|September 13, 2021
Use of Faecal Transplantation with a Novel Diet for Mild to Moderate Active Ulcerative Colitis: The CRAFT UC Randomised Controlled TrialChen Sarbagili Shabat, Franco Scaldaferri, Eran Zittan, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 7, 2020
Early Indolent Course of Crohn's Disease in Newly Diagnosed Patients Is Not Rare and Possibly PredictableHenit Yanai, Idan Goren, Lihi Godny, et al.
Inflammatory Bowel Diseases|February 2, 2012
Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of responseLior Katz, Javier P Gisbert, Beth Manoogian, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
United European Gastroenterology Journal|August 19, 2020
Vedolizumab is effective and safe in elderly inflammatory bowel disease patients: a binational, multicenter, retrospective cohort studyNathaniel Aviv Cohen, Nikolas Plevris, Uri Kopylov, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|September 3, 2018
Effectiveness and safety of vedolizumab for maintenance treatment in inflammatory bowel disease-The Israeli real world experienceUri Kopylov, Irit Avni-Biron, Yulia Ron, et al.
Inflammatory Bowel Diseases|February 9, 2017
Efficacy and Safety of Vedolizumab for Induction of Remission in Inflammatory Bowel Disease-the Israeli Real-World ExperienceUri Kopylov, Yulia Ron, Irit Avni-Biron, et al.
Alimentary Pharmacology & Therapeutics|September 28, 2022
Ustekinumab during pregnancy in patients with inflammatory bowel disease: a prospective multicentre cohort studyIrit Avni-Biron, Tali Mishael, Eran Zittan, et al.
The Lancet. Gastroenterology & Hepatology|November 5, 2021
The Crohn's disease exclusion diet for induction and maintenance of remission in adults with mild-to-moderate Crohn's disease (CDED-AD): an open-label, pilot, randomised trialHenit Yanai, Arie Levine, Ayal Hirsch, et al.
Journal of Crohn'S & Colitis|May 9, 2024
Faecal Transplantation for Ulcerative Colitis From Diet Conditioned Donors Followed by Dietary Intervention Results in Favourable Gut Microbial Profile Compared to Faecal Transplantation AloneHaim Leibovitzh, Chen Sarbagili Shabat, Ayal Hirsch, et al.
United European Gastroenterology Journal|March 28, 2020
Safety and effectiveness of ustekinumab for induction of remission in patients with Crohn's disease: A multicenter Israeli studyAriella Bar-Gil Shitrit, Ami Ben-Ya'acov, Matan Siterman, et al.
Journal of Crohn'S & Colitis|September 13, 2021
Use of Faecal Transplantation with a Novel Diet for Mild to Moderate Active Ulcerative Colitis: The CRAFT UC Randomised Controlled TrialChen Sarbagili Shabat, Franco Scaldaferri, Eran Zittan, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 7, 2020
Early Indolent Course of Crohn's Disease in Newly Diagnosed Patients Is Not Rare and Possibly PredictableHenit Yanai, Idan Goren, Lihi Godny, et al.
Inflammatory Bowel Diseases|February 2, 2012
Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of responseLior Katz, Javier P Gisbert, Beth Manoogian, et al.
Pageof 5